Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy
Authors:
- Sabrina da Conceição PereiraSPSabrina da Conceição Pereira
- Bérengère BenoitBBBérengère Benoit
- Francisco Carlos Amanajás de Aguiar JuniorFJFrancisco Carlos Amanajás de Aguiar Junior
- Stéphanie ChanonSCStéphanie Chanon
- Aurélie Vieille‐MarchisetAVAurélie Vieille‐Marchiset
- Jérome RuzzinJRJérome Ruzzin
- Hubert VidalHVHubert Vidal
- Ana Elisa ToscanoATAna Elisa Toscano
Open Access
- 26 October 2021
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 12 (6) , 2122-2133
Abstract
Background: Cerebral palsy (CP) associates cerebral function damages with strong locomotor defects and premature sarcopenia. We previously showed that fibroblast growth factor 19 (FGF19) exerts hypertrophic effects on skeletal muscle and improves muscle mass and strength in mouse models with muscle atrophy. Facing the lack of therapeutics to treat locomotor dysfunctions in CP, we investigated whether FGF19 treatment could have beneficial effects in an experimental rat model of CP.Methods: Cerebral palsy was induced in male Wistar rat pups by perinatal anoxia immediately after birth and by sensorimotor restriction of hind paws maintained until Day 28. Daily subcutaneous injections with recombinant human FGF19 (0.1 mg/kg bw) were performed from Days 22 to 28. Locomotor activity and muscle strength were assessed before and after FGF19 treatment. At Day 29, motor coordination on rotarod and various musculoskeletal parameters (weight of tibia bone and of soleus and extensor digitorum longus (EDL) muscles; area of skeletal muscle fibres) were evaluated. In addition, expression of specific genes linked to human CP was measured in rat skeletal muscles.Results: Compared to controls, CP rats had reduced locomotion activity (−37.8% of distance travelled, P < 0.05), motor coordination (−88.9% latency of falls on rotarod, P < 0.05) and muscle strength (−25.1%, P < 0.05). These defects were associated with reduction in soleus (−51.5%, P < 0.05) and EDL (−42.5%, P < 0.05) weight, smaller area of muscle fibres, and with lower tibia weight (−38%, P < 0.05). In muscles from rats submitted to CP, changes in the expression levels of several genes related to muscle development and neuromuscular junctions were similar to those found in wrist muscle of children with CP (increased mRNA levels of Igfbp5, Kcnn3, Gdf8, and MyH4 and decreased expression of Myog, Ucp2 and Lpl). Compared with vehicle‐treated CP rats, FGF19 administration improved locomotor activity (+53.2%, P < 0.05) and muscle strength (+25.7%, P < 0.05), and increased tibia weight (+13.8%, P < 0.05) and soleus and EDL muscle weight (+28.6% and +27.3%, respectively, P < 0.05). In addition, it reduced a number of very small fibres in both muscles (P < 0.05). Finally, gene expression analyses revealed that FGF19 might counteract the immature state of skeletal muscles induced by CP.Conclusions: These results demonstrate that pharmacological intervention with recombinant FGF19 could restore musculoskeletal and locomotor dysfunction in an experimental CP model, suggesting that FGF19 may represent a potential therapeutic strategy to combat the locomotor disorders associated with CP.Keywords
Funding Information
- Agence Nationale de la Recherche (BONTO‐19)
This publication has 40 references indexed in Scilit:
- Transcriptional Abnormalities of Hamstring Muscle Contractures in Children with Cerebral PalsyPLOS ONE, 2012
- Effects of fetal exposure to lipopolysaccharide, perinatal anoxia and sensorimotor restriction on motor skills and musculoskeletal tissue: Implications for an animal model of cerebral palsyExperimental Neurology, 2011
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen SynthesisScience, 2011
- Impact of viral-mediated IGF-I gene transfer on skeletal muscle following cast immobilizationAmerican Journal of Physiology-Endocrinology and Metabolism, 2010
- Novel transcriptional profile in wrist muscles from cerebral palsy patientsBMC Medical Genomics, 2009
- Complex nature of SNP genotype effects on gene expression in primary human leucocytesBMC Medical Genomics, 2009
- Maintaining blood–brain barrier integrity: Pericytes perform better than astrocytes during prolonged oxygen deprivationJournal of Cellular Physiology, 2008
- Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis ratAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- FGF-19, A NOVEL FIBROBLAST GROWTH FACTOR WITH UNIQUE SPECIFICITY FOR FGFR4Cytokine, 1999
- Myogenin gene disruption results in perinatal lethality because of severe muscle defectNature, 1993